SCHEMBL5798564

SCHEMBL5798564

NCCc1ccc(-n2cnnc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
QPCT Q16769 1/20 0.52
TAAR1 Q96RJ0 9/20 0.45
HTR2A P28223 4/20 0.45
CYP1A2 P05177 2/20 0.45
CYP2A6 P11509 2/20 0.45
LOXL2 Q9Y4K0 2/20 0.45
KDM4E B2RXH2 1/20 0.45
ALDH1A1 P00352 1/20 0.45
HTR1A P08908 1/20 0.45
ADRA2A P08913 1/20 0.45
SLC6A2 P23975 1/20 0.45
CYP2C19 P33261 1/20 0.45
HTR3A P46098 1/20 0.45
BACE1 P56817 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CYP2C9 P11712 1/20 0.44
BLM P54132 1/20 0.43
KMT2A Q03164 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8346704 0.79 QPCT (0.56) QPCTCYP1A2KDM4EALDH1A1BACE1
SCHEMBL5801060 0.77 LMNA (0.65) CYP1A2LOXL2CYP2C19CYP2C9KMT2A
SCHEMBL27531306 0.77 VHL (0.57) TAAR1HTR2ACYP1A2CYP2A6LOXL2
SCHEMBL28002115 0.76 CYP1A2 (0.64) QPCTCYP1A2CYP2C9KMT2ACA12
Hydrochloric Acid SCHEMBL21382427 0.75 VHL (0.55) TAAR1HTR2ACYP1A2CYP2A6LOXL2
SCHEMBL1352015 0.75 MAPT (0.56) QPCTCYP1A2KDM4EALDH1A1L3MBTL1
SCHEMBL27594315 0.74 QPCT (0.55) QPCTCYP1A2CYP2C9KMT2ACA12
SCHEMBL6499444 0.74 QPCT (0.55) QPCTTAAR1CYP1A2CYP2A6KDM4E
SCHEMBL224548 0.74 TAAR1 (0.72) TAAR1HTR2ACYP1A2CYP2A6LOXL2
Hydrochloric Acid SCHEMBL3668004 0.71 BLM (0.74) TAAR1HTR2ACYP1A2CYP2A6LOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1572209-A4 NOVEL QUINOXALINONE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS MERCK & CO INC (US) 2006-12-06 EP disclosed
EP-1572209-A1 NOVEL QUINOXALINONE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS Merck & Co., Inc. (US) 2005-09-14 EP disclosed
US-6908921-B2 Quinoxalinone derivatives as bradykinin B1 antagonists MERCK & CO., INC. (US) 2005-06-21 US disclosed
US-20050020591-A1 2-Quinoxalinone derivatives as bradykinin antagonists and novel compounds SU DAI-SHI (US) 2005-01-27 US disclosed
US-20040132733-A1 Novel quinoxalinone derivatives as bradykinin B1 antagonists MERCK & CO., INC. 2004-07-08 US disclosed
WO-2004054584-A1 NOVEL QUINOXALINONE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS MERCK & CO., INC. (US) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020591-A1 2-Quinoxalinone derivatives as bradykinin antagonists and novel compounds BDKRB1, BDKRB2, LTB4R2 QPCT 729/4885TAAR1 568/4885HTR2A 272/4885
US-20040132733-A1 Novel quinoxalinone derivatives as bradykinin B1 antagonists BDKRB1, BDKRB2, LTB4R2 QPCT 958/4885TAAR1 506/4885HTR2A 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.